ArticleScientific reports2025
Development of a preclinical X-rays minibeam Monte Carlo treatment planning system.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined minibeam and conventional radiotherapy reduces severe skin toxicity and improves tumor control.Scientific reports · 2026Article
- Radioluminescence 3D dose reconstruction for FLASH and conventional radiotherapy.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Minibeam Radiation Therapy (MBRT) delivers spatially fractionated beams, generating alternating high-dose peaks and low-dose valleys, with potential benefits in tumor control and normal tissue sparing. This study presents the development of a Monte Carlo (MC) Treatment Planning System (TPS) for preclinical MBRT, preceded by an investigation of various collimator configurations and a comparison of MC simulations with experimental data. Multiple simulations were conducted to evaluate different combinations of attenuator materials (lead, tungsten) and spacer materials (PMMA, air), as well as various slit widths (0.5-1 mm). Among the tested configurations, tungsten and PMMA emerged as the most suitable materials. As expected, the peak-to-valley dose ratio (PVDR) decreased with depth, while the full-width at half-maximum (FWHM) slightly increased. Fluka and Topas simulations showed good agreement with experimental measurements from gafchromic MDV3 films. A MC-based TPS was implemented to compute dose distributions in mice using CT data and to extract key dosimetric parameters, including PVDR and FWHM. Simulations were performed for a subcutaneous glioblastoma tumor as a case study. Within the tumor volume, the TPS estimated PVDR values ranging from 27 to 16 and a depth-dependent FWHM increase of about 5%. This system provides a robust platform for preclinical MBRT research, supporting treatment planning and delivery optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.